Up-front combination of RAF and MEK inhibitors, however, may delay or prevent the common mechanisms of treatment-emergent resistance that occur with monotherapy and improves progression-free and overall survival in patients with advanced melanoma [8,9,10]. Here, MAP2K7 is linked to melanoma.